SCYNEXIS is a biotechnology company. Co. is developing its primary product candidate, ibrexafungerp, as a broad-spectrum, intravenous/oral agent for multiple fungal indications in both the community and hospital settings. Ibrexafungerp, the initial representative of a class of antifungal agents called triterpenoids and designated by the suffix -fungerp, is a structurally distinct glucan synthase inhibitor and has shown in vitro and in vivo activity against a range of human fungal pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces species. The SCYX stock yearly return is shown above.
The yearly return on the SCYX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2018 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SCYX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|